First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors

Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC

(2023) Vasiliki Stravokefalou et al.   Frontiers in Immunology

Tumor eradication by hetIL-15 locoregional therapy correlates with an induced intratumoral CD103intCD11b+ dendritic cell population

(2023) Dimitris Stellas et al.   Cell Reports

Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers

(2022) Mark P. Rubinstein et al.   JOURNAL OF IMMUNOLOGY

ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential

(2022) Wujun Chen et al.   Frontiers in Immunology

Heterodimeric IL-15 in Cancer Immunotherapy

(2021) Cristina Bergamaschi et al.   Cancers

Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

(2021) Kevin Conlon et al.   Journal for ImmunoTherapy of Cancer

Rationale for IL-15 superagonists in cancer immunotherapy

(2020) Karin M. Knudson et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

IL-15 in the Combination Immunotherapy of Cancer

(2020) Thomas A. Waldmann et al.   Frontiers in Immunology

Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10

(2020) Cristina Bergamaschi et al.   Journal for ImmunoTherapy of Cancer

Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink

(2020) John A. Hangasky et al.   Frontiers in Immunology

Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy

(2019) Karin M. Knudson et al.   Journal for ImmunoTherapy of Cancer

Harnessing NK Cells for Cancer Treatment

(2019) Paola Minetto et al.   Frontiers in Immunology

Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques

(2018) Cristina Bergamaschi et al.   CYTOKINE

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

(2018) John M Wrangle et al.   LANCET ONCOLOGY

The potential and promise of IL-15 in immuno-oncogenic therapies

(2017) Tanya O. Robinson et al.   IMMUNOLOGY LETTERS

Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion

(2016) Sinnie Sin Man Ng et al.   CLINICAL CANCER RESEARCH

A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses

(2016) Bai Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

IL-15Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists

(2016) Mélanie Desbois et al.   JOURNAL OF IMMUNOLOGY

IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas

(2016) Peter S. Kim et al.   Oncotarget

Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

(2015) Kevin C. Conlon et al.   JOURNAL OF CLINICAL ONCOLOGY

The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy

(2015) T. A. Waldmann   Cancer Immunology Research

Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells

(2014) C Bergamaschi et al.   GENE THERAPY

Preassociation of IL-15 with IL-15R -IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action

(2014) S. Dubois et al.   JOURNAL OF IMMUNOLOGY

The Common  -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands

(2014) A. L. Kinter et al.   JOURNAL OF IMMUNOLOGY

Circulating IL-15 exists as heterodimeric complex with soluble IL-15R  in human and mouse serum

(2012) C. Bergamaschi et al.   BLOOD

Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model

(2010) P. Yu et al.   CLINICAL CANCER RESEARCH